Company intelligence / Profile preview

Atopia Therapeutics

Geneva, Geneva Canton, Switzerlandatopiatx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Preclinical studies of ATP-R13 have shown promising results in murine models of allergic asthma, demonstrating improved airway responsiveness, reduced airway remodeling, and decreased inflammation. The therapy induces immune tolerance by promoting regulatory T cell development and aims to address the root cause of allergic diseases rather than just symptoms. Clinical development preparations are ongoing.[3][7]

Therapeutic areas: PulmonologyDermatologyImmunology
Modalities: Oral immunotherapyrecombinant protein (bacterial protein-derived)immunomodulatory biologic[1][5][9]
Industry: Biotech

Drug pipeline

1 asset

ATP-R13

Preclinical

Partnerships

None publicly disclosed as of May 2024.

Beyond the preview

Go deeper on Atopia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atopia Therapeutics.

Explore the full profile